Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
now 4,625-5.00
Can see this doubling!
why would they suspend share dealing? Its a great deal... and one to buy / hold imo.
Really good sign when a multi-billion dollar company like Rosen's Diversified Inc wants to invest and partner with you.
Interesting news, a placing at 5p a share! Will they suspend share dealing today?
Holding and waiting for sales and profits in 2019.
Goodbody sounds as though they have managed to achieve a TRANSAM promotion for Excellagen with their latest agreement as below. Production must be at max capacity.
All sounds very positive for future manufacturing:
https://storage.googleapis.com/wzukusers/user-26831283/documents/5cdd5415c1b4alKu2A7m/PR_Excellagen_Launch_SAWC_5_16_19.pdf
Could do with an update on Chondromimetic; which could be our own game changer.
Market for Excellagen in the US alone is 6m to 13m suffering foot ulcers, so manufacturing income has good potential. The Hardman report on Page 2 said there are 11 development contracts of which Excellagen was just the first.
Started to generate revenues.....
https://storage.googleapis.com/wzukusers/user-26831283/documents/5cc70c760c641AosTzV6/PR_Roadmap_4_29_19.pdf
For anyone not familiar with the link to COS:
https://www.globenewswire.com/news-release/2019/01/03/1680440/0/en/UPDATE-Generex-Biotechnology-Makes-Major-Advance-On-22-Billion-Wound-Care-Market-Announcing-Milestone-Agreement.html
Latest promotion
https://storage.googleapis.com/wzukusers/user-26831283/documents/5cb8abaf65d6ehL2p6eg/PR_Olaregen_DLS_4_18_19.pdf
6 mins into interview below launching mid April with limited stock by September will have built stocks up for a regional pitch. So revenue from Excellagen manufacture will only just be coming on stream.
Tino, "COS took hit last year from restructuring the New Zealand branch"
Tino, cost cutting is always fine, but the real driver of profits is always increasing revenue. 4 million in revenue will never make anyone rich, and the problem here is that they just aren't growing fast enough to get to sustainability.
https://www.investorschampion.com/channel/podcasts/more-than-money-collagen-solutions
this a good listen.
Soupchicken,
COS took hit last year from restructuring the New Zealand branch, i think these figures are encouraging and around the same value as the expected savings from operating costs.
imo of course.
Soup kitchen not so sure why you have that comment in quotes Hardman does not have 3 March report last report was dated 22 Feb. They estimated cash at year end would be £1.4m and it is £1.7m. If the numbers are within forecast should be no shortage of cash quite the opposite next year. None of the numbers below include Chondromimetic and should be cash positive without any contribution.
" I thought the main issue is that it just can't grow it's sales fast enough. " 3 Mar
I think this Trading Update confirms this. Cash burn too high for the sales. ie when's the next fund raise.
According to the Hardman report annual losses on previous estimated income was £948k this will be lower due to higher revenue. On a conservative basis £100k lower for revenue plus a reduction for the investment sale. The half year loss was £620k(Hardman) which leaves a loss in 2nd half of about £180k. Allowing for new contracts and Excellagen production this is beginning to look pretty close to positive territory.
Looks like the revenue run rate is higher as all the new contracts will not have contributed to a full years income
Looks like they are making good progress, beating market expectations for the year is very positive.
Definetly some Bed and ISA action going on with COS imo.
suspect there has been for a while here.
Any thoughts?
Interesting few weeks coming up .... Chondromimetic aside we should be getting a top line read out post the FY end. I am really interested to get some insight in to where the underlying business currently stands versus some of the predictions made. Particularly that by end of FY19 we should be cash flow break even on a run-rate basis .... if they have hit this mark (in truth if they are even close) and it is sustainable this is huge for the company in the longer term.
In addition during April it is likely we will get news on Chondromimetic and some of the animal data on the other proprietary products. Fingers crossed on all of the above.